期刊
FRONTIERS IN PHARMACOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.529881
关键词
artemisinins; antitumor; mechanism of action; clinical trials; therapeutic approach
资金
- Scientific Research Project of Education Department in Hunan Province [17C0973]
- National Natural Science Foundation of China [81874212]
- Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University [2017TP1020]
- Huxiang High-Level Talent Innovation Team [2018RS3072]
Artemisinin and its derivatives have shown broad-spectrum antitumor activitiesin vitroandin vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据